Cargando…

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

BACKGROUND: Data are scarce on immunogenicity of COVID-19 vaccines in patients with autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to investigate the effect of different immunosuppressive drugs on antibody development after COVID-19 vaccination in patients with aut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boekel, Laura, Steenhuis, Maurice, Hooijberg, Femke, Besten, Yaëlle R, van Kempen, Zoé L E, Kummer, Laura Y, van Dam, Koos P J, Stalman, Eileen W, Vogelzang, Erik H, Cristianawati, Olvi, Keijzer, Sofie, Vidarsson, Gestur, Voskuyl, Alexandre E, Wieske, Luuk, Eftimov, Filip, van Vollenhoven, Ronald, Kuijpers, Taco W, van Ham, S Marieke, Tas, Sander W, Killestein, Joep, Boers, Maarten, Nurmohamed, Michael T, Rispens, Theo, Wolbink, Gertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346242/ https://www.ncbi.nlm.nih.gov/pubmed/34396154 http://dx.doi.org/10.1016/S2665-9913(21)00222-8

Ejemplares similares

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
por: Boekel, Laura, et al.
Publicado: (2022)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
por: van Dam, Koos P. J., et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2022)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic
por: Boekel, L., et al.
Publicado: (2021)

The Ligands for Human IgG and Their Effector Functions
por: de Taeye, Steven W., et al.
Publicado: (2019)

Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines
por: Van Coillie, Julie, et al.
Publicado: (2023)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

IgG Subclasses and Allotypes: From Structure to Effector Functions
por: Vidarsson, Gestur, et al.
Publicado: (2014)

Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases
por: Dekkers, Gillian, et al.
Publicado: (2018)

Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
por: van Dam, Koos P.J., et al.
Publicado: (2023)

Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
por: van Dam, Koos P. J., et al.
Publicado: (2023)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
por: Wieske, Luuk, et al.
Publicado: (2022)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

IgG Glyco-Engineering to Improve IVIg Potency
por: Bruggeman, Christine W., et al.
Publicado: (2018)

Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
por: Wieske, Luuk, et al.
Publicado: (2022)

Fingerprick blood samples to measure serum natalizumab concentrations
por: Toorop, Alyssa A, et al.
Publicado: (2022)

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
por: van Vollenhoven, Ronald F, et al.
Publicado: (2023)

On the Perplexingly Low Rate of Transport of IgG2 across the Human Placenta
por: Einarsdottir, Helga K., et al.
Publicado: (2014)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up
por: Vogelzang, E. H., et al.
Publicado: (2018)

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Human IgE does not bind to human FcRn
por: Brinkhaus, Maximilian, et al.
Publicado: (2022)

Factors affecting IgG4-mediated complement activation
por: Oskam, Nienke, et al.
Publicado: (2023)

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab
por: de Jong, Tamarah D, et al.
Publicado: (2015)

Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation
por: Kustiawan, Iwan, et al.
Publicado: (2018)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i1uoibef8tni1vpr3fd727mjgb